301 related articles for article (PubMed ID: 11313894)
1. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
[TBL] [Abstract][Full Text] [Related]
2. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
[TBL] [Abstract][Full Text] [Related]
3. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
10. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.
Dallol A; Forgacs E; Martinez A; Sekido Y; Walker R; Kishida T; Rabbitts P; Maher ER; Minna JD; Latif F
Oncogene; 2002 May; 21(19):3020-8. PubMed ID: 12082532
[TBL] [Abstract][Full Text] [Related]
11. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
12. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.
Yu MY; Tong JH; Chan PK; Lee TL; Chan MW; Chan AW; Lo KW; To KF
Int J Cancer; 2003 Jun; 105(2):204-9. PubMed ID: 12673680
[TBL] [Abstract][Full Text] [Related]
14. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.
Dammann R; Takahashi T; Pfeifer GP
Oncogene; 2001 Jun; 20(27):3563-7. PubMed ID: 11429703
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
16. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers.
Hesson L; Dallol A; Minna JD; Maher ER; Latif F
Oncogene; 2003 Feb; 22(6):947-54. PubMed ID: 12584574
[TBL] [Abstract][Full Text] [Related]
17. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.
Wagner KJ; Cooper WN; Grundy RG; Caldwell G; Jones C; Wadey RB; Morton D; Schofield PN; Reik W; Latif F; Maher ER
Oncogene; 2002 Oct; 21(47):7277-82. PubMed ID: 12370819
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.
Yoon JH; Dammann R; Pfeifer GP
Int J Cancer; 2001 Oct; 94(2):212-7. PubMed ID: 11668500
[TBL] [Abstract][Full Text] [Related]
19. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
20. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]